avapro has been researched along with Stroke in 21 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke." | 9.16 | A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 9.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 9.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation." | 8.86 | Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? ( Lane, DA; Lip, GY, 2010) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 7.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Stroke is a major cause of mortality and disability worldwide." | 6.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "Participants in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF, but not randomized to oral anticoagulation, were categorized as having preserved versus reduced ejection fraction." | 5.20 | Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. ( Connolly, SJ; Hart, RG; Healey, JS; Hohnloser, SH; McAlister, FA; Pfeffer, MA; Sandhu, RK; Yuan, F; Yusuf, S, 2015) |
| "To determine whether 30 days of treatment with atorvastatin, or irbesartan, initiated within 96 h of symptom onset improves recovery from acute ischemic stroke." | 5.16 | A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. ( Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB, 2012) |
| " In the 3371 patients randomized to vitamin K antagonists and the 3335 patients randomized to clopidogrel plus aspirin in ACTIVE-W, the hazard ratio (HR) and 95% confidence intervals (95% CIs) for subsequent death associated with the occurrence of non-fatal stroke was 5." | 5.14 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. ( Budaj, A; Chrolavicius, S; Connolly, SJ; De Caterina, R; Morais, J; Pogue, J; Renda, G; Yusuf, S, 2010) |
| "In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation." | 5.13 | Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). ( Connolly, SJ; De Caterina, R; Flaker, G; Hart, RG; Healey, JS; Hohnloser, SH; Pfeffer, MA; Pogue, J; Yusuf, S, 2008) |
| "Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy." | 5.12 | Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. ( Chrolavicius, S; Connolly, S; Hart, R; Hohnloser, S; Pfeffer, M; Pogue, J; Yusuf, S, 2006) |
| "The Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study demonstrated a significant increase in myocardial infarction events with dabigatran compared with warfarin, provoking renewed interest in whether vitamin K antagonists are useful drugs for the prevention of myocardial infarction in high-risk patients with atrial fibrillation." | 4.86 | Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? ( Lane, DA; Lip, GY, 2010) |
| "Compared with other angiotensin-receptor blockers, telmisartan and valsartan were both associated with a lower risk of admission to hospital for acute myocardial infarction, stroke or heart failure among older adults with diabetes and hypertension." | 3.79 | Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study. ( Antoniou, T; Camacho, X; Gomes, T; Juurlink, DN; Mamdani, MM; Yao, Z, 2013) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 3.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| "Stroke is a major cause of mortality and disability worldwide." | 2.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 15 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Culman, J | 1 |
| Jacob, T | 1 |
| Schuster, SO | 1 |
| Brolund-Spaether, K | 1 |
| Brolund, L | 1 |
| Cascorbi, I | 1 |
| Zhao, Y | 1 |
| Gohlke, P | 1 |
| Antoniou, T | 1 |
| Camacho, X | 1 |
| Yao, Z | 1 |
| Gomes, T | 1 |
| Juurlink, DN | 1 |
| Mamdani, MM | 1 |
| Kikuchi, K | 1 |
| Tancharoen, S | 1 |
| Ito, T | 1 |
| Morimoto-Yamashita, Y | 1 |
| Miura, N | 1 |
| Kawahara, K | 1 |
| Maruyama, I | 1 |
| Murai, Y | 1 |
| Tanaka, E | 1 |
| Hasegawa, Y | 1 |
| Nakagawa, T | 1 |
| Uekawa, K | 1 |
| Ma, M | 1 |
| Lin, B | 1 |
| Kusaka, H | 1 |
| Katayama, T | 1 |
| Sueta, D | 1 |
| Toyama, K | 1 |
| Koibuchi, N | 1 |
| Kim-Mitsuyama, S | 1 |
| Sandhu, RK | 1 |
| Hohnloser, SH | 3 |
| Pfeffer, MA | 3 |
| Yuan, F | 1 |
| Hart, RG | 4 |
| Yusuf, S | 5 |
| Connolly, SJ | 4 |
| McAlister, FA | 1 |
| Healey, JS | 3 |
| Tan, CH | 1 |
| Tang, SC | 1 |
| Lin, RJ | 1 |
| Jeng, JS | 1 |
| Lip, GY | 1 |
| Lane, DA | 1 |
| De Caterina, R | 2 |
| Pogue, J | 4 |
| Chrolavicius, S | 3 |
| Budaj, A | 1 |
| Morais, J | 1 |
| Renda, G | 1 |
| Tebbe, U | 1 |
| Bramlage, P | 1 |
| Lüders, S | 1 |
| Cuneo, A | 1 |
| Sistig, P | 1 |
| de Haan, F | 1 |
| Schmieder, R | 1 |
| Böhm, M | 1 |
| Paar, WD | 1 |
| Schrader, J | 1 |
| Flather, M | 1 |
| Joyner, CD | 1 |
| Holtkamp, FA | 1 |
| de Zeeuw, D | 1 |
| de Graeff, PA | 1 |
| Laverman, GD | 1 |
| Berl, T | 1 |
| Remuzzi, G | 1 |
| Packham, D | 1 |
| Lewis, JB | 1 |
| Parving, HH | 1 |
| Lambers Heerspink, HJ | 1 |
| Khan, M | 2 |
| Kamal, AK | 2 |
| Beer, C | 1 |
| Blacker, D | 1 |
| Bynevelt, M | 1 |
| Hankey, GJ | 1 |
| Puddey, IB | 1 |
| Karpov, IuA | 1 |
| Shimamura, T | 1 |
| Masui, M | 1 |
| Torii, M | 1 |
| Nakajima, M | 1 |
| Graham, D | 2 |
| Hamilton, C | 1 |
| Beattie, E | 1 |
| Spiers, A | 1 |
| Dominiczak, AF | 2 |
| Connolly, S | 1 |
| Hart, R | 1 |
| Pfeffer, M | 2 |
| Hohnloser, S | 2 |
| Flaker, G | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249795] | Phase 3 | 9,016 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00243178] | Phase 3 | 6,706 participants (Actual) | Interventional | 2003-07-31 | Terminated | ||
| PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy[NCT03392948] | 1,080 participants (Anticipated) | Observational [Patient Registry] | 2018-02-09 | Active, not recruiting | |||
| Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)[NCT02426944] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-10-13 | Completed | ||
| A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure[NCT03088072] | Phase 4 | 75 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is the death over the duration of the follow-up whatever the cause, cardiovascular or non-cardiovascular. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 949 |
| Placebo | 929 |
The considered event is the first overnight hospital stay for HF over the duration of the follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 482 |
| Placebo | 551 |
The considered event is the overnight hospital stay for any CV cause other than Heart Failure over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 1186 |
| Placebo | 1174 |
The considered event is the first occurence of any HF episode defined as evidence of signs and symptoms of HF with or without hospitalization over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 699 |
| Placebo | 767 |
The considered event is the first occurrence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) over the duration of follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 379 |
| Placebo | 411 |
The first co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal) or vascular death - after validation by the Event Adjudication Committee (EAC). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Vascular death | |
| Irbesartan | 963 | 136 | 367 | 460 |
| Placebo | 963 | 123 | 407 | 433 |
The second co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal), vascular death or hospitalization for heart failure - after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Vascular death | - Hospitalization for heart failure | |
| Irbesartan | 1236 | 122 | 340 | 331 | 443 |
| Placebo | 1291 | 112 | 375 | 291 | 513 |
4 reviews available for avapro and Stroke
| Article | Year |
|---|---|
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou | 2013 |
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Biphenyl Compounds; D | 2010 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
[Clinical hypertensiology: analysis of trials completed in 2001-2002].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitor | 2002 |
6 trials available for avapro and Stroke
11 other studies available for avapro and Stroke
| Article | Year |
|---|---|
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2017 |
Comparative effectiveness of angiotensin-receptor blockers for preventing macrovascular disease in patients with diabetes: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compo | 2013 |
Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Bl | 2016 |
Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker.
Topics: Aged, 80 and over; Angioedema; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; | 2010 |
Follow-up of cardiovascular risk markers in hypertensive patients treated with irbesartan: results of the i-SEARCH Plus Registry.
Topics: Aged; Albuminuria; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Card | 2010 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Biphenyl Compounds; Cl | 2011 |
Atrial fibrillation, is warfarin the only option for stroke prevention?
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
The unmet need of patients with atrial fibrillation: AVERROES and the novel oral anticoagulants.
Topics: Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Aspirin; Atrial Fibrillation; Biphenyl Comp | 2011 |
Hypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Biphenyl Comp | 2004 |
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba | 2004 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |